Form 4 for OLMA Olema Pharmaceuticals, Inc.
Accepted 2026-02-17 00:00:00 ET · period of report 2026-02-02 · accession 0002110895-26-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-17 | 2026-02-02 | OLMA | Austin Sasha Lu | VP of Fin, Ctrl | A - Grant | $0.00 | +11.7K | 16.2K | +261% | $0 |
| D | 2026-02-17 | 2026-02-02 | OLMA | Austin Sasha Lu | VP of Fin, Ctrl | A - Grant | $0.00 | +29.2K | 29.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-02 | A | A | 11,700 | $0.00 | 16,188 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2026-02-02 | A | A | 29,250 | $0.00 | 29,250 | D | $25.65 · — to 2036-02-01 | 29,250 Common Stock | (F1) 25% of the shares subject to the option vest on February 2, 2027, and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. |